CAGE Bio Reports Strong Results from its Phase 2b Atopic Dermatitis Trial

The Phase 2b study enrolled 180 patients ≥12 years of age at 16 sites across the United States. A large majority of patients (~85%) had moderate AD, while 9% had mild and 6% had severe AD, all with affected body surface area <10%.

The trial met primary and secondary endpoints, demonstrating best-in-class treatment success, rapid itch reduction, and a favorable safety profile.

......[click link before for full article]

SOUTHLAKE, Texas, June 10, 2025 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to veverimer for the treatment of anti-glomerular basement membrane disease (anti-GBM), an ultra-rare life-threatening condition characterized by acute renal failure associated with the presence of auto-immune antibodies with affinity for the glomerular basement membrane.   ......[click link before for full article]

SOUTHLAKE, Texas, April 24, 2025 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical late-stage biopharmaceutical company focusing on the prevention and treatment of cardiac, renal, and metabolic diseases, today announced the completion of enrollment (n=400) in PROTECT, a pivotal Phase 3 trial evaluating the effect of RBT-1 on reducing the risk of post-operative complications in patients undergoing cardiac surgery (NCT06021457). The trial enrolled 423 patients across 40 trial sites in the United States (US) and Canada. Topline results from the study are anticipated in third quarter of this year.......[click link before for full article]

DALLAS, TX — Oct. 10, 2024  — Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases today announced a productive FDA meeting for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP). Based on the regulatory feedback provided in the meeting, Nanoscope will commence with submission of a Biologics License Application (BLA) in Q1 2025.......[click link before for full article]

The inTUMO Therapeutics board has accepted an offer from a buyer to acquire all outstanding stock. The board of directors of Cage Bio did a spin-off of their Solid Tumor assets in May of 2022, and issued stockholders in Cage Bio their pro rata in inTumo Therapeutics, Inc. The “Solid Tumor Assets” were Cage assets that were  exclusively related to the research, development, and commercialization of assets with respect to oncology therapies employing tissue ablation via tumoral injection or catheter-based delivery of ionic liquids. As part of the transaction, CKG Management will be issuing a capital return to all investors that participated in the CJV, LLC and C2JV, LLC offerings. Investors in these entities should have already received a communication, but our encouraged to contact their CKG Management representative if they have not received any details.  

Cardiology and Heart Surgery

Despite advancements over the past several decades to help minimize the post-operative complications of cardiac surgery, many patients still experience an inflammatory response to cardiopulmonary bypass, when doctors use a heart-lung machine to continue to pump blood while the heart is arrested. This response can lead to prolonged ventilation, bleeding, stroke, and renal dysfunction, often increased time in the intensive care unit (ICU) and prolonged length of stay.....[click link before for full article]

Novel Pre-op Agent Reduces Anemia, Transfusion in Cardiac Surgery Patients

The pharmacologic preconditioning agent RBT-1, a first-in-class drug for patients undergoing cardiothoracic surgery, reduces the incidence of anemia, blood transfusion and use of supplemental iron in these patients, according to research presented at the 2023 annual meeting of the American Society for Enhanced Recovery and Perioperative Medicine.

A combination of stannic protoporfin and iron sucrose, RBT-1 upregulates anti-inflammatory, antioxidant and iron-scavenging pathways. It was granted a Breakthrough Therapy designation by the FDA in July 2023, after results from a phase 2, double-blind, placebo-controlled trial in patients undergoing coronary artery bypass graft and/or cardiac valve surgery on cardiopulmonary bypass found significant improvement in clinically meaningful end points, including days in the ICU, ventilator time, hospital length of stay and cardiopulmonary.....[click link before for full article]

Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa

• MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events 
• Data from the Phase 2b RESTORE trial demonstrate clinically meaningful vision improvement in legally blind individuals with progressive and permanent neurodegeneration of the retina
• RESTORE is the first randomized, controlled trial of a mutation-agnostic gene therapy for a genetic disease
• Nanoscope anticipates submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the second half of 2024

DALLAS, March 26, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced positive top-line results after the completion of the 2-year Phase 2b RESTORE randomized, controlled clinical trial of its lead program, MCO-010, a mutation-agnostic gene therapy for patients with permanent and severe vision loss from advanced retinitis pigmentosa (RP). .....[click link before for full article]

Renibus Announces Leadership Transition

Jeffrey Keyser, RPh, JD, PhD, co-Founder and Former co-CEO, Appointed President & CEO 

SOUTHLAKE, Texas, March 21, 2024 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic diseases, today announced a transition in its leadership structure. As part of this change, Frank Stonebanks, former co-CEO, has left the company to pursue new opportunities.  Renibus wishes Mr. Stonebanks the best in his future endeavors. Jeffrey Keyser, RPh, JD, PhD, co-founder and former co-CEO, has been appointed President and CEO of Renibus.

Dr. Keyser is a veteran of the biopharmaceutical industry with a track record of success. Prior to co-founding Renibus, Dr. Keyser invented the Mucinex product line for Adams Respiratory Therapeutics, Inc. and co-founded ZS Pharma, Inc. (acquired by Astra Zeneca Plc).   His leadership has been instrumental in Renibus' success to date and he is well positioned to lead the company into its next phase of growth and innovation.

Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa

• FDA and EU Regulators provide consistent advice that visual acuity may serve as primary endpoint to evaluate the effectiveness of MCO-010 in the treatment of low-vision retinitis pigmentosa (RP) patients 
• Regulatory feedback provides clarity for potential path to approval in the US and in Europe for MCO-010 in RP; Nanoscope preparing for immediate execution

DALLAS, Jan. 18, 2024 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today provided an update following recent regulatory discussions with the U.S. Food and Drug Administration ("FDA") and from the Scientific Advice meeting with the ...regarding the regulatory path of MCO-010 for the treatment of RP .....[click link before for full article]

Renibus Announces Publication of Results from Phase 2 Study Evaluating RBT-1 as a Pre-Conditioning Agent to Reduce Post-Operative Complications Following Cardiothoracic Surgery

increases the risk of post-operative complications

Phase 3 PROTECT study ongoing, top line data anticipated Q3 2025

SOUTHLAKE, Texas, Jan. 9, 2024 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced publication in E-Clinical Medicine, part of The Lancet Discovery Science, of results from the Phase 2 study evaluating RBT-1, the Company's first-in-a-new-class preconditioning agent, under investigation to reduce post-operative complications.....[click link before for full article]

Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board

DALLAS, Dec. 4, 2023 /PRNewswire/ -- Nanoscope Therapeutics (Nanoscope), a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced the appointment of Glenn Sblendorio as Chairman of the Board, effective immediately. With more than 30 years of exemplary experience marked by extensive executive leadership in the ophthalmic industry, Mr. Sblendorio will support Nanoscope in reaching its strategic vision.............[click link below for full article]

OncoNano Medicine Announces Positive Preclinical Data for ON-BOARD™ IL-12 Program at SITC 2023 Annual Meeting

SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine, Inc. today presented positive preclinical data describing the effective delivery of interleukin-12 (IL-12) with the ON-BOARD™ platform technology at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).

The study findings show that encapsulation of a therapeutic IL-12 fusion protein (IL-12Fc) for tumor specific delivery and pH-dependent activation was achieved using the ON-BOARD™ polymeric micelle technology. The study also found that ON-BOARD™ significantly improved the tolerability of IL-12Fc, as compared to unencapsulated IL-12. The encapsulated IL-12Fc demonstrated potent anti-tumor efficacy and durable anti-tumor memory in the MC38 colorectal cancer model. ONM-412, the development product candidate with the IL-12 encapsulated in the ON-BOARD™ polymeric micelle system, is advancing through IND-enabling activities............[click link below for full article]

Renibus Announces First Patient Enrolled in PROTECT Phase 3 Study of RBT-1 to Reduce Post-operative Complications After Cardiothoracic Surgery

Pivotal trial will evaluate the effect of RBT-1 as a preconditioning agent in people undergoing cardiothoracic surgery

Estimated 600K CABG and valve repair surgeries in US/year, creating a large initial market for RBT-1

PROTECT enrollment on track, NDA filing anticipated early 2026

SOUTHLAKE, Texas, Oct. 25, 2023 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic diseases, today announced that the first patient has been dosed in the pivotal Phase 3 PROTECT trial of RBT-1, the Company's first-in-a-new-class preconditioning agent under investigation to reduce post-operative complications following cardiothoracic surgery. PROTECT is expected to be conducted at approximately 35 sites in the United States and Canada............[click link below for full article]

Renibus Therapeutics Announces Final Close of Upsized Series B Financing, Bringing Total Round to $72 Million

SOUTHLAKE, Texas, Sept. 12, 2023 /PRNewswire/ -- Renibus Therapeutics, Inc., ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic diseases, today announced the close of an extension to its Series B financing round, bringing the total amount raised to $72 million.   Renibus' investors are comprised of existing and new investors, including leaders in the cardiac surgery community............[click link below for full article]

CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic Liquid formulation of 1% Tofacitinib In Patients with Atopic Dermatitis

SAN CARLOS, CA and FORT WORTH, TX / ACCESSWIRE / August 3, 2023 / CAGE Bio, Inc. (hereinafter "CAGE Bio") a biotechnology company focused on developing innovative drug therapies for localized treatment of immuno-dermatological disorders, today announced positive results from its randomized, vehicle controlled, phase 2 study evaluating the safety and efficacy of CGB-500, an ionic liquid formulation of 1% Tofacitinib, in patients with Atopic Dermatitis (AD)...........[click link below for full article]

Renibus Therapeutics Announces $47 Million Financing to Advance Lead Program RBT-1 Through Pivotal Phase 3 Trial

SOUTHLAKE, Texas, July 18, 2023 /PRNewswire/ -- Renibus Therapeutics, Inc., ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal diseases, today announced raising $47 million from the initial closings of a Series B financing ..........[click link below for full article]

Renibus Therapeutics Announces Breakthrough Therapy Designation from US FDA for RBT-1 for the Reduction in Risk of Post-Operative Complications in Patients Undergoing Cardiothoracic Surgery

SOUTHLAKE, Texas, July 11, 2023 /PRNewswire/ -- Renibus Therapeutics, Inc., ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to RBT-1 for the reduction in risk of post-operative complications in patients undergoing cardiothoracic surgery, and confirmed its alignment with the Company's planned Phase 3 pivotal trial.  ..........[click link below for full article]

Renibus Reports Positive Final Results from Phase 2 Study of RBT-1, a First-in-Class Preconditioning Agent for Patients Undergoing Cardiothoracic Surgery, at the American Association for Thoracic Surgery (AATS) Meeting

RBT-1 achieved the primary biomarker endpoint, as well as several key clinical outcome endpoints; positive data supports the potential for RBT-1 to improve postoperative outcomes in cardiothoracic surgery-

RBT-1 as a preconditioning agent has the potential to provide patient benefits in multiple surgical settings where organ injury during surgery increases the risk of post-operative complications-

-Planned pivotal Phase 3 study of RBT-1 to be initiated in June 2023-

SOUTHLAKE, Texas, May 7, 2023 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal diseases, today presented positive final results from a Phase 2 trial evaluating RBT-1 (stannic protoporfin/iron sucrose) in patients undergoing elective cardiac surgery during an oral presentation..........[click link below for full article]

Nanoscope Therapeutics Announces Presentation of Key Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa at the ARVO Annual Meeting

• 100% (18/18) MCO-010 patients experienced a clinically meaningful improvement in vision-guided mobility (MLYMT), near-field object recognition (MLSDT) or visual acuity (BCVA) (p=0.007 vs sham)
• 94.4% (17/18) MCO-010 patients showed vision improvement in the MLYMT or BCVA (p=0.008 vs sham)
• 88.9% (16/18) of MCO-010 patients experienced a clinically meaningful 2 or more luminance level improvement in MLYMT or MLSDT (p=0.02 vs sham)
• Favorable safety profile for MCO-010 with no serious or severe adverse event

DALLAS, April 27, 2023 /PRNewswire/ — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced the presentation of key data from its Phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE clinical trial. ..........[click link below for full article]

Nanoscope’s gene therapy nabs Phase II win in retinitis pigmentosa

In another win for the gene therapy space, Dallas, Texas-based Nanoscope Therapeutics announcedpositive topline data in a Phase IIb trial of MCO-010 in advanced retinitis pigmentosa.

The 27-patient Phase IIb RESTORE trial (NCT04945772) met its primary efficacy endpoint of the Multi-Luminance Y-mobility Test (MLYMT), which measures patients’ ability to navigate between LEDs lights in a room of varying luminance. In the study, 18 patients received MCO-010 while 9 received a sham intravitreal injection. ..........[click link below for full article]

Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa

DALLAS, March 30, 2023 /PRNewswire/ -- Nanoscope Therapeutics Inc., today announced topline results from the Phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE clinical trial (NCT04945772)  of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration in advanced retinitis pigmentosa (RP), irrespective of gene mutation. MCO-010 has received both orphan drug and fast track designations from the U.S. Food and Drug Administration (FDA) ..........[click link below for full article]

OncoNano Medicine Presents Data from Phase 2 Pegsitacianine Study at Society of Surgical Oncology (SSO) 2023 International Congress on Surgical Cancer Care

SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine, Inc. presented data from a Phase 2 study of pegsitacianine, a pH-sensitive fluorescent nanoprobe for image-guided cancer surgery, at the Society of Surgical Oncology (SSO) 2023 International Congress on Surgical Cancer Care, occurring March 22-25 in Boston, MA. Data from the study revealed that the primary endpoint was achieved in 50% of the evaluable patients undergoing peritoneal carcinomatosis surgery ..........[click link below for full article]

Renibus Therapeutics Announces Oral Presentation on RBT-1 Phase 2 Results at 2023 Society of Critical Care Medicine (SCCM) Meeting

-RBT-1 met the primary biomarker endpoint as well as several key clinical endpoints; positive data supports the potential for RBT-1 to improve postoperative outcomes in cardiothoracic surgery-

-RBT-1 treatment demonstrated a statistically significant reduction in ICU days and 30-day cardiopulmonary readmission rates; patients treated with RBT-1 had reduced time on ventilator as well as reduced rates of atrial fibrillation, hypervolemia, acute kidney injury, troponin I levels and anemia, indicating a broad, organ protective effect consistent with the mechanism of action of RBT-1-

-SCCM has awarded a STAR Research Achievement Award to the presentation as a recognition of excellence in critical care research-

-Planned pivotal Phase 3 study of RBT-1 to be initiated in Q1 2023-

SOUTHLAKE, Texas, Jan. 19, 2023 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biotech company focusing on the prevention and treatment of cardio-renal diseases, today announced that an oral presentation will be delivered on the positive results of RBT-1 from a Phase 2 Study at the Society for Critical Care Medicine (SCCM) 2023 Critical Care Congress at the Moscone Center in San Francisco, CA from January 21- 24, 2023 ..........[click link below for full article]

Renibus Therapeutics Announces Positive 30-Day Topline Data from RBT-1 Phase 2 Trial

SOUTHLAKE, Texas, Jan. 5, 2023 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biotech company focusing on the prevention and treatment of cardio-renal diseases, today announced positive 30-day topline data from RBT-1 in a Phase 2 trial. RBT-1 met the primary endpoint of increasomarkers of cytoprotective preconditioning in a multicenter, double-blind, placebo controlled, Phase 2 study in patients undergoing coronary artery bypass graft (CABG) and/or cardiac valve surgery on cardiopulmonary bypass. ..........[click link below for full article]

SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine, Inc. today announced that the Cancer Prevention and Research Institute of Texas (CPRIT) will convert $18.4 million in grant award funding into an equity investment in OncoNano. Proceeds of the financing will be used to support OncoNano’s Phase 3 clinical trials in the U.S. and Europe for pegsitacianine, an innovative real-time imaging agent used in intraoperative surgical resection of solid tumors, and accelerate the advancement of the company’s first internal therapeutic development program .... [ click link below for full article]

SOUTHLAKE, Texas--(BUSINESS WIRE)-- OncoNano Medicine, Inc. announced positive results from its preclinical study of ONM-501, a novel dual-activating polyvalent STING agonist for immuno-oncology applications. The data, presented at The American Association for Cancer Research (AACR) Virtual Conference on Tumor Immunology and Immunotherapy, demonstrate strong efficacy in multiple tumor models .... [ click link below for full article]

SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine, Inc., a clinical-stage company utilizing the principles of molecular cooperativity in drug design to exploit universal tumor and immune targets to diagnose and treat cancer, today announced a multi-year collaboration with The University of Texas Southwestern Medical Center (UTSW) to discover and conduct translational research of novel cancer therapeutics that leverage . ... [ click link below for full article]

BEDFORD, Texas, September 16, 2021 /Bizjournals -- Nanoscope Therapeutics is on a mission to restore sight to those with age-related macular degeneration. And early trials of its therapy show it can do just that.

To help fuel its Phase 2b trials, the Bedford-based biotech startup announced landing a $1.5 million Small Business Research Innovation grant from the National Eye Institute as it looks to bring its optogenetic gene therapy. ... [ click link below for full article]

BEDFORD, Texas, July 19, 2021 /PRNewswire/ -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for treatment of retinal degenerative diseases, today announced that the first patient had been dosed in its Phase 2b clinical trial of MCO-010, an ambient-light activatable optogenetic monotherapy to restore vision in patients with retinitis pigmentosa (RP).e. ... [ click link below for full article]

Financing round led by Advantech healthcare investment team 

Funds will support Phase 3 program for pegsitacianine and IND-enabling activities for ONM-501

SOUTHLAKE, Texas--(BUSINESS WIRE)-- OncoNano Medicine, Inc. today announced the raise of an approximate $50 million Series B financing led by the healthcare investment team at Advantech Capital, a China-based cross border institutional investment fund. Proceeds of the financing will be used, in part, to support the Phase 3 clinical trials in the U.S. and Europe. ... [ click link below for full article]

Meanwhile, Texas-based biotech company Nanoscope Therapeutics is expected to begin a clinical trial of an opsin that responds to ambient light this summer. Nanoscope’s synthetic opsin molecule responds to a broad range of wavelengths, and the patients don’t require goggles, says Samarendra Mohanty, president of Nanoscope. 

In Nanoscope’s previous trial, conducted in India, 11 patients regained some vision beginning 4-6 weeks after receiving the injections, Mohanty says. Those gains have persisted for one year so far, he says. Some of the patients reportedly see well enough to use a cell phone, read large letters, and travel unassisted to the study center. ... [ click link below for full article]

Nanoscope's RP gene therapy, which has received orphan drug designation from the US Food and Drug Administration, uses a proprietary AAV2 vector to deliver the MCO genes into the retina. This mutation-independent gene therapy involves a single injection through the eye administered in a doctor's office. 

• First reported clinically meaningful functional improvement by optogenetic therapy 
• Significant dose-dependent improvement of visual acuity at 16 weeks, previously reported at the American Academy of Ophthalmology 2020 annual meeting, continues through 52 weeks in severe retinitis pigmentosa patients
•  [ click link below for full article]

CAGE Bio Inc., a biotechnology company focused on developing innovative therapies for infection, inflammation and immunology, announced dosing of the first patient in its Phase 2 clinical trial for the treatment of inflammatory lesions of rosacea.

The 12-week randomized double-blind vehicle-controlled trial is testing CAGE Bio's novel ionic-liquid based product CGB-400 Topical Gel. Patients diagnosed with moderate to severe rosacea with inflammatory lesions on their face will be enrolled in the study at four sites in the US and randomized to an active or vehicle arm.

 ... [ click link below for full article]

Renibus plans to enroll 126 subjects at up to 20 sites across the United States, Canada, Australia, and New Zealand

DALLAS, Texas, March 11, 2021 (GLOBE NEWSWIRE) -- Renibus Therapeutics® (“Renibus”), a clinical-stage biotech company focusing on the prevention, treatment, and diagnostic testing of kidney disease, announced today that the company has initiated a Phase 2 study evaluating the efficacy of RBT-1 on acute kidney injury (AKI) prevention in subjects undergoing coronary artery bypass graft (CABG) and/or cardiac valve surgery. The study plans to enroll 126 patients in up to 20 sites across the United States, Canada, Australia ... [ click link below for full article]

- With no currently approved therapies for the prevention or treatment of platinum-induced toxicity, RBT-3 has the potential to fill a critical unmet medical need.

Dallas, Texas, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotech company focusing on the prevention, treatment, and diagnostic testing of kidney disease, announced today the publication of a peer-reviewed article in the scientific journal Nephrology Dialysis Transplant demonstrating that its investigational treatment for iron deficiency anemia, RBT-3, reduces cisplatin-induced kidney toxicity in an experimental preclinical model... [ click link below for full article]

Study Reveals Compelling Data for a New Nanoparticle-based Immuno-Therapeutic to Treat Cancer

SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine, Inc. today announced that a research paper titled “Prolonged activation of innate immune pathways by a polyvalent STING agonist” published in Nature Biomedical Engineering shows that a pH-sensitive nanoparticle-based drug developed by Dr. Jinming Gao and team at the University of Texas Southwestern Medical Center (UTSW) could boost the body’s innate immune pathways in the treatment of multiple cancers with a unique mechanism of activating the STimulator of INterferon Genes (STING). OncoNano licensed this technology from UTSW for further development as part of the company’s proprietary ... [ click link below for full article]